Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.
Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.
Viruses. 2024 Sep 28;16(10):1539. doi: 10.3390/v16101539.
In a time of climate change, population growth, and globalization, the risk of viral spread has significantly increased. The 21st century has already witnessed outbreaks of Severe Acute Respiratory Syndrome virus (SARS-CoV), Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2), Ebola virus and Influenza virus, among others. Viruses rapidly adapt and evade human immune systems, complicating the development of effective antiviral countermeasures. Consequently, the need for novel antivirals resilient to viral mutations is urgent. In this study, we developed a CRISPR-Cas13b system to target SARS-CoV-2. Interestingly, this system was also efficient against SARS-CoV, demonstrating broad-spectrum potential. Our findings highlight CRISPR-Cas13b as a promising tool for antiviral therapeutics, underscoring its potential in RNA-virus-associated pandemic responses.
在气候变化、人口增长和全球化的时代，病毒传播的风险显著增加。21 世纪已经见证了严重急性呼吸系统综合症病毒（SARS-CoV）、严重急性呼吸系统综合症病毒 2 型（SARS-CoV-2）、埃博拉病毒和流感病毒等的爆发。病毒迅速适应并逃避人体免疫系统，这使得开发有效的抗病毒对策变得复杂。因此，迫切需要对病毒突变具有抗性的新型抗病毒药物。在这项研究中，我们开发了一种针对 SARS-CoV-2 的 CRISPR-Cas13b 系统。有趣的是，该系统对 SARS-CoV 也有效，显示出广谱潜力。我们的研究结果强调了 CRISPR-Cas13b 作为抗病毒治疗的有前途的工具，突出了其在与 RNA 病毒相关的大流行应对中的潜力。
